智通财经APP讯，四环医药(00460)发布公告，于2025年10月15日，受托人已就股份奖励计划于市场上购 买合共925.5万股公司股份。 ...

四环医药(00460)发布公告，于2025年10月15日，受托人已就股份奖励计划于市场上购买合共925.5万股 公司股份。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 自願公告 根據股份獎勵計劃購買股份 此 乃 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」或「四環醫藥」，連 同 其 附 屬 公 司， 統 稱 為「本集團」）作 出 的 自 願 公 告。 兹 提 述 本 公 司 日 期 為 二 零 二 二 年 十 月 二 十 六 日 的 公 告（「該公告」），內 容 有 關 （其 中 包 括）本 公 司 採 納 二 零 二 二 年 股 份 獎 勵 計 劃（「股份獎勵計劃」）。除 文 義 另 有 所 指 外，本 公 告 所 用 詞 彙 與 該 公 告 所 界 定 者 具 有 相 同 涵 義。於 二 零 二 五 年 十 月 十 五 日，受 託 ...

格隆汇10月15日丨四环医药(00460.HK)宣布，关建议分拆及公司附属公司轩竹生物于联交所主板独立上 市。于全球发售完成后，分拆公司于2025年10月15日在联交所主板上市，而分拆公司H股于2025年10月 15日上午九时正开始于联交所主板买卖。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 本 公 告 僅 供 參 考，並 不 構 成 收 購、購 買 或 認 購 任 何 證 券 的 邀 請 或 要 約。 董 事 會 欣 然 宣 佈，於 全 球 發 售 完 成 後，分 拆 公 司 於 二 零 二 五 年 十 月 十 五 日 在 聯 交 所 主 板 上 市，而 分 拆 公 司H股於二零二五年十月十五日上午九時正開始 於 聯 交 所 主 板 買 賣。 緒 言 本公告並不構成在美國境內或在任何其他司法管轄區提呈出售要約或招攬購 買 任 何 證 券 的 要 約，倘 未 根 據 任 何 該 等 司 法 管 轄 區 的 證 券 法 辦 理 登 記 或 未 獲 批 准 而 於 上 述 地 區 進 行 上 述 要 約、招 攬 或 出 售 即 屬 違 法。本 公 告 所 述 的 證 券 將 不會根據經修訂的1933年 美 國 證 券 法（「證券法」）登 記 ...

Market Performance - The Hang Seng Healthcare Index decreased by 2.74% as of October 14, 2025, with mixed performance among constituent stocks [1] - The Hang Seng Healthcare ETF (513060) fell by 1.74%, with a latest price of 0.68 CNY, but has seen an 18.15% increase over the past three months [1] - The Hong Kong Stock Connect Innovative Drug Selection Index dropped by 3.58%, with the latest price of the corresponding ETF (520690) at 0.94 CNY, reflecting a decline of 2.28% [2] - The CSI Pharmaceutical 50 Index decreased by 1.24%, with the latest price of the Pharmaceutical 50 ETF (159838) at 0.63 CNY, showing an 11.34% increase over the past three months [2] Liquidity and Trading Activity - The Hang Seng Healthcare ETF had a turnover of 12.72% and a trading volume of 884 million CNY, indicating active market participation [1] - The Hong Kong Innovative Drug Selection ETF recorded a turnover of 21.74% with a trading volume of 90.47 million CNY [2] - The Pharmaceutical 50 ETF had a turnover of 1.01% and a trading volume of 1.66 million CNY, with an average daily trading volume of 6.33 million CNY over the past week [3] Regulatory and Market Developments - The National Healthcare Security Administration issued a notice to strengthen the regulation of retail pharmacies, targeting "dual pricing" practices, which may accelerate compliance in the pharmacy sector [3] - Boteng Co., Ltd. expects a revenue growth of 17%-21% year-on-year for the first three quarters, indicating a recovery in the CDMO sector driven by global client pipeline expansion [3] - Four Seasons Pharmaceutical has acquired a stake in Swiss Suisselle SA, gaining exclusive rights to the CELLBOOSTER® product, enhancing its international brand collaboration and product matrix [3] Institutional Insights - The overall signal for the pharmaceutical sector is neutral, with regulatory pressures on retail pharmacies but resilience in CDMO and medical aesthetics sectors [4] - Short-term focus is on the sustainability of performance recovery for companies like Boteng, while mid-term attention is on international collaborations in medical aesthetics and growth in the innovative drug outsourcing industry [4] Fund Flows and Performance - The Hang Seng Healthcare ETF saw a net inflow of 12.05 million CNY, accumulating 177 million CNY over the past 15 trading days [6] - The Hong Kong Innovative Drug Selection ETF reached a record high of 434 million shares, with a net inflow of 2.89 million CNY recently [7] - The CSI Pharmaceutical 50 Index includes major companies like WuXi AppTec and Hengrui Medicine, with the top ten stocks accounting for 59.46% of the index [8]

Core Viewpoint - The company, Four Seasons Pharmaceutical, has announced a strategic investment in Swiss aesthetic company Suisselle SA, marking a significant step in its global expansion strategy in the medical aesthetics industry [2] Group 1: Investment Details - Four Seasons Pharmaceutical will complete its investment in Suisselle SA by September 2025, having signed a subscription agreement [2] - The partnership grants Four Seasons exclusive agency rights for the CELLBOOSTER® product line, allowing deep involvement in its operations and development [2] Group 2: Company Background - Suisselle, established in 2010, is a leading manufacturer of water-light needle products, with its CELLBOOSTER® series utilizing patented CHAC technology [2] - The company has expanded its business to 43 countries, showcasing its international reach and market presence [2] Group 3: Strategic Implications - The collaboration will enable Four Seasons to leverage Suisselle's established platform in Europe to accelerate the promotion and sales of its self-developed medical aesthetic products in European and other overseas markets [2] - The partnership aims to continuously introduce innovative products from Suisselle and other European sources, enhancing the domestic medical aesthetic product portfolio [2] - This investment is described as a key step in Four Seasons' global strategy for its medical aesthetics sector [2]

Group 1 - Jiuan Medical plans to repurchase shares worth no less than 300 million yuan and no more than 600 million yuan, with a maximum repurchase price of 53.5 yuan per share, to maintain company value and shareholder rights [1] - The current share price of 38.19 yuan represents a discount of approximately 28% compared to the repurchase cap, signaling potential valuation recovery [1] - The repurchased shares are intended to be sold within 12 months after the announcement, providing short-term price stability and future funding flexibility for business transformation [1] Group 2 - Lingbei's drug Bexicaserin has been recognized as a breakthrough therapy by the National Medical Products Administration (NMPA) in China for treating developmental epileptic encephalopathy (DEE) [2] - Bexicaserin is a novel oral 5-HT2C receptor agonist designed to reduce cardiovascular risks, marking a significant milestone in Lingbei's development in China [2] Group 3 - Four Rings Pharmaceutical has announced an investment in Swiss medical aesthetics company Suisselle SA, strengthening their long-term partnership [3] - This investment allows Four Rings to maintain exclusive rights to the CELLBOOSTER® product in China and participate deeply in its operations and development [3] - The collaboration aims to accelerate the promotion and sales of Four Rings' self-developed aesthetic products in Europe and other overseas markets [3] Group 4 - Fudan Zhangjiang's application for the drug Obechol acid tablets for treating primary biliary cholangitis was not approved by the NMPA due to non-compliance with registration requirements [4] - The project has incurred approximately 125 million yuan in R&D investment, which will not significantly impact the company's current financial status [4] - The company needs to review the reasons for the rejection and optimize its pipeline to enhance future R&D efficiency [4] Group 5 - Sunshine Nuohuo's BTP4507 has received approval for clinical trials from the NMPA, targeting primary hypertension patients with inadequate response to monotherapy [5] - BTP4507 is a compound formulation designed to address multiple hypertension targets, catering to the needs of over 300 million hypertensive patients in China [5] - If successful in clinical trials, this drug could open new growth avenues for the company, although it will face competition from similar combination therapies [5]

四环医药(00460)发布公告，于2025年10月13日，受托人已就股份奖励计划于市场上购买合共1000万股 本公司股份(股份)。 ...

智通财经APP讯，四环医药(00460)发布公告，于2025年10月13日，受托人已就股份奖励计划于市场上购 买合共1000万股本公司股份(股份)。 ...